From the Problem Gambling Clinic and the Women and Addictive Disorders Core, Women’s Health Research, Yale University; the Neuroimaging Section, MIRECC, West Haven Veterans Affairs Hospital, West Haven, Conn.; and the Department of Psychiatry, Yale University School of Medicine. Address correspondence and reprint requests to Dr. Potenza, Yale University School of Medicine, Connecticut Mental Health Center, Rm. S-104, 34 Park St., New Haven, CT 06519; firstname.lastname@example.org (e-mail).Dr. Potenza has received research support from the NIH (National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism), the U.S. Department of Veterans Affairs, the Connecticut Department of Mental Health and Addictive Services, Women’s Health Research at Yale University, OrthoMcNeil, and Mohegan Sun. He has consulted for Boehringer Ingelheim and Somaxon and has financial interests in Somaxon. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.